Índice

• • ·Reflections on the past

    Página :317

     
• • ·Genetic risk of cancer: a tale of diversity from the Middle East

    Página :318-319

    Khawla S Al-Kuraya

     
• • ·Medical treatment for active breast cancer brain metastases

    Página :319-321

    Caroline Bailleux, Thomas Bachelot

     
• • ·Frontline chemotherapy-free induction for mantle cell lymphoma

    Página :321-322

    Umberto Vitolo, Mattia Novo

      
• • ·Importing oncology trials from China: a bridge over troubled waters?

    Página :323-325

    Harpreet Singh, Richard Pazdur

     
• • ·Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?

    Página :325-328

    Gabriele Antonarelli, Carmine Valenza, Erica L Mayer, Sibylle Loibl, Giuseppe Curigliano

     
• • ·Progression-free survival: it is time for a new name

    Página :328-330

    Bishal Gyawali, Elizabeth Eisenhauer, Michelle Tregear, Christopher M Booth

     
• • ·Retraction and republication—Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

    Página :330

    
• • ·Code of practice needed for samples donated by trial participants

    Página :e89

    Robert Coleman, Arlene Chan, Carlos Barrios, David Cameron, Luis Costa, Mitch Dowsett, David Harrison, Anthony Howell, Denis Lacombe, Mairead MacKenzie, Miguel Martin, Stuart McIntosh, Adrienne Morgan, Martine Piccart, Tanja Spanic

    
• • ·Code of practice needed for samples donated by trial participants – Sponsor’s reply

    Página :e91

    Doug Warner, Anthony Glennane, Byeong Yoon, Hossam Saad

    
• • ·Climate crisis and cancer: perspectives from the hardest hit

    Página :e92

    Michelle Ann B Eala, Janine Patricia G Robredo, Edward Christopher Dee, Vivian Lin, Alfredo Mahar Francisco A Lagmay

    
• • ·ROAR trial: which treatment is effective after progression?

    Página :e93

    Osman Sütcüoğlu, Kadriye Bir Yücel, Aytuğ Üner, Ozan Yazici, Nuriye Özdemir

    
• • ·ROAR trial: which treatment is effective after progression? – Authors’ reply

    Página :e94

    Patrick Y Wen, Paul Burgess, Palanichamy Ilankumaran, Vivek Subbiah

    
• • ·Survivorship after neoadjuvant chemotherapy

    Página :e95

    Jin Zhang, Chaoyang Liang, Wenquan Niu

    
• • ·Survivorship after neoadjuvant chemotherapy – Authors’ reply

    Página :e96

    Christina Yau, Marie Osdoit, Laura J Esserman, W Fraser Symmans

    
• • ·Post-protocol therapy and informative censoring in the CANDOR study

    Página :e97

    Tomer Meirson, Gal Markel, Vinay Prasad, Aaron M Goodman, Ghulam Rehman Mohyuddin

     
• • ·Post-protocol therapy and informative censoring in the CANDOR study – Authors’ reply

    Página :e98

    Saad Z Usmani, Chuang Li, Mihaela Obreja, Meletios Dimopoulos

    
• • ·HLA-A*03 and response to immune checkpoint blockade in patients with cancer

    Página :e99

    Leonidas N Diamantopoulos, Leonard J Appleman

    
• • ·6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting

    Página :e100

    Naysha Becerra-Chauca, Wendy Nieto-Gutierrez, Alvaro Taype-Rondan

    
• • ·Correction to Lancet Oncol 2022; 23: 207–08

    Página :e101

    
• • ·Malaysia to ban tobacco sales to people born after 2005

    Página :331

    Manjulika Das

     
• • ·New agreement to strengthen paediatric cancer treatment in Libya

    Página :332

    Manjulika Das

     
• • ·NICE withdraws quality standard on colorectal cancer treatment after “lack of consensus”

    Página :333

    Emma Wilkinson

      
• • ·Mozambique takes on cancer burden challenges

    Página :334

    Manjulika Das

     
• • ·President Biden outlines plans for Cancer Moonshot 2.0

    Página :335

    Elizabeth Gourd

     
• • ·Gender disparities in access to paediatric cancer care in India

    Página :336

    Manjulika Das

     
• • ·US Congress considers new health-care bill for burn pit-exposed veterans

    Página :e102

    Bryant Furlow

     
• • ·IAEA and Brazilian Navy to provide new arsenal to fight breast cancer: mammography on a ship

    Página :e103

    Marcia Triunfol

     
• • ·Bangladesh decentralises cancer care services to expand access to care

    Página :e104

    Manjulika Das

     
• • ·Yale Precision Medicine Tumor Board: reawakening the guardian of the genome

    Página :337-338

    Michael J Grant, Karin E Finberg, Zenta Walther, Stacey M Stein, Jill Lacy, Joseph P Eder, Sarah B Goldberg

    Esquema Esquema  
• • ·Still Max: Max Dean asks how we can fix ourselves

    Página :339

    Catherine Lucas

     
• • ·Sentinel nodes and breast cancer: an old story

    Página :340

    Emmanuel Drouin, Jean-Marc Classe, Patrick Hautecoeur

     
• • ·Genetic predisposition to cancer across people of different ancestries in Qatar: a population-based, cohort study

    Página :341-352

    Mohamad Saad, Younes Mokrab, Najeeb Halabi, Jingxuan Shan, Rozaimi Razali, Khalid Kunji, Najeeb Syed, Ramzi Temanni, Murugan Subramanian, Michele Ceccarelli, Qatar Genome Programme Research Consortium, Arash Rafii Tabrizi, Davide Bedognetti, Lotfi Chouchane, Said I Ismail, Wadha Al-Muftah, Radja Badji, Hamdi Mbarek, Dima Darwish, Tasnim Fadl, Heba Yasin, Maryem Ennaifar, Rania Abdellatif, Fatima Alkuwari, Muhammad Alvi, Yasser Al-Sarraj, Chadi Saad, Eleni Fethnou, Fatima Qafoud, Eiman Alkhayat, Nahla Afifi, Sara Tomei, Wei Liu, Stephan Lorenz, Najeeb Syed, Hakeem Almabrazi, Fazulur R Vempalli, Ramzi Temanni, Tariq Abu Saqri, Mohammedhusen Khatib, Mehshad Hamza, Tariq Abu Zaid, Ahmed El Khouly, Tushar Pathare, Shafeeq Poolat, Rashid Al-Ali, Omar Albagha, Souhaila Al-Khodor, Mashael Alshafai, Ramin Badii, Lotfi Chouchane, Xavier Estivill, Khalid Fakhro, Hamdi Mbarek, Younes Mokrab, Jithesh V Puthen, Karsten Suhre, Zohreh Tatari

    Resumen Resumen Esquema Esquema   
• • ·Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial

    Página :353-361

    Min Yan, Quchang Ouyang, Tao Sun, Limin Niu, Jin Yang, Li Li, Yuhua Song, Chunfang Hao, Zhanhong Chen, Armando Orlandi, Naohiro Ishii, Kazuaki Takabe, Gianluca Franceschini, Francesco Ricci, Claire Verschraegen, Zhenzhen Liu, Mengwei Zhang, Huimin Lv, Liping Liu, Xiaohong Yang, Huawu Xiao, Zhichao Gao, Xiaorui Li, Fangyuan Dong, Xiuchun Chen, Jianghua Qiao, Guifang Zhang

    Resumen Resumen Esquema Esquema   
• • ·Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

    Página :362-373

    Matthew R Smith, Howard I Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N Lara, Evan Y Yu, Daniel J George, Kim N Chi, Fred Saad, Olof Ståhl, David Olmos, Daniel C Danila, Gary E Mason, Byron M Espina, Xin Zhao, Karen A Urtishak, Peter Francis, Angela Lopez-Gitlitz, Karim Fizazi, GALAHAD investigators, Francis Parnis, Anthony M. Joshua, Lisa G. Horvath, Christopher Steer, Gavin Marx, Shahneen Sandhu, Howard Gurney, Thomas Ferguson, Siska Van Bruwaene, Daisy Luyten, Peter Schatteman, Nicolaas Lumen, Luc Dirix, Jean-Charles Goeminne, Thierry Gil, Emmanuel Seront, Christof Vulsteke, Celio Kussumoto, Fabio A. Franke, Fabricio Augusto Martinelli de Oliveira, Andrea Juliana Pereira de Santana Gomes, Hélio Pinczowski, Daniel D’Almeida Preto, Luis Eduardo Zucca, Giuliano Santos Borges, Andre M. Murad, Fred Saad, Kim N. Chi, Yves Fradet, Neil E. Fleshner, Urban Emmenegger, Klaus Brasso, Karim Fizazi, Stephane Culine, Antoine Thiery-Vuillemin, Florence Joly, Aude Fléchon, Werner Hilgers, Jean-Christophe Eymard, Delphine Borchiellini, Philippe Barthélémy, Raanan Berger, Raya Leibowitz-Amit, Wilmosh Mermershtain, Keren Rouvinov, Avivit Peer, Svetlana Kovel, Avishay Sella, Martijn P. Lolkema, Alfonsus J.M. van den Eertwegh, Johannes Voortman, Maureen J. Aarts, Jourik A. Gietema, Choung-Soo Kim, Young-Deuk Choi, Byung-Ha Chung, Rustem A. Gafanov, Evgeniy Kopyltsov, Evgeny A. Usynin, Joan Carles, Begoña Mellado, José Pablo Maroto, Jesús García-Donás, Juan Francisco Rodríguez Moreno, Ignacio Durán, Begoña Pérez-Valderrama, Elena Castro, David Olmos, María José Méndez-Vidal, David Lorente Estellés, Regina Gironés Sarrió, José Muñoz-Langa, Urbano Anido Herranz, Javier Puente Vázquez, Enrique Castellanos, Martin Hellström, Anders Widmark, Ingela Franck Lissbrant, Åsa Jellvert, Cecilia Külich, René Blom, Olof Ståhl, Po-Hui Chiang, Chih-Hsiung Kang, Yen-Chuan Ou, Shian-Shiang Wang, Hsi-Chin Wu, Yu-Chuan Lu, Gerhardt Attard, Vincent Khoo, Amit Bahl, Prasad Kellati, Omi Parikh, Rajaguru Srinivasan, Jason F. Lester, John N. Staffurth, Heather H. Cheng, Eleni Efstathiou, Patrick G. Pilié, Daniel J. George, Lawrence I. Karsh, W. Kevin Kelly, Daniel C. Danila, Paul R. Sieber, Matthew R. Smith, Elisabeth I. Heath, Ulka N. Vaishampayan, Thomas W. Flaig, Hamid Emamekhoo, Jacek K. Pinski, Arash Rezazadeh Kalebasty, Joseph J. Maly, Helen Moon

    Resumen Resumen Esquema Esquema   
• • ·Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial

    Página :374-381

    Dean A Fennell, Amy King, Seid Mohammed, Alastair Greystoke, Sarah Anthony, Charlotte Poile, Nada Nusrat, Molly Scotland, Vina Bhundia, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Amrita Bajaj, Cathy Richards, Peter Wells-Jordan, Anne Thomas, MiST2 study group, Dean A. Fennell, Amy King, Alastair Greystoke, Sarah Anthony, Sam Moody, Charlotte Poille, Nada Nusrat, Molly Scotland, Vina Bhundia, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G. Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Amrita Bajaj, Cathy Richards, Peter Wells-Jordan, Adrian Nicolson, Judith Underwood, Azmina Sodha-Ramdeen, Caroline Cowley, Shaun Barber, Anne Thomas

    Resumen Resumen Esquema Esquema   
• • ·Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

    Página :382-392

    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Rosie Bradley, Jeremy Braybrooke, Richard Gray, Robert K Hills, Zulian Liu, Hongchao Pan, Richard Peto, David Dodwell, Paul McGale, Carolyn Taylor, Prudence A Francis, Michael Gnant, Francesco Perrone, Meredith M Regan, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Lucy Davies, Fran Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Raimund Jakesz, Christian Fesl, Olivia Pagani, Richard Gelber, Michelino De Laurentiis, Sabino De Placido, Ciro Gallo, Kathy Albain, Stewart Anderson, Rodrigo Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith Bliss, Etienne Brain, Lisa Carey, Robert Coleman, Jack Cuzick, Nancy Davidson, Lucia Del Mastro, Angelo Di Leo, James Dignam, Mitch Dowsett, Bent Ejlertsen, Matthew Goetz, Pam Goodwin, Pat Halpin-Murphy, Dan Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori Pierce, Philip Poortmans, Kathleen I Pritchard, Vinod Raina, Daniel Rea, John Robertson, Emiel Rutgers, Tanja Spanic, Joseph Sparano, Guenther Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Tim Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Sandra M Swain

    Resumen Resumen Esquema Esquema   
• • ·Pain and health-related quality of life with olaparib versus physician’s choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial

    Página :393-405

    Antoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, Guilhem Roubaud, Giuseppe Procopio, Neal Shore, Karim Fizazi, Gabriel dos Anjos, Gwenaelle Gravis, Jae Young Joung, Nobuaki Matsubara, Daniel Castellano, Arnold Degboe, Chris Gresty, Jinyu Kang, Allison Allen, Christian Poehlein, Fred Saad

    Resumen Resumen Esquema Esquema   
• • ·Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

    Página :406-415

    Michael L Wang, Preetesh Jain, Shuangtao Zhao, Hun Ju Lee, Loretta Nastoupil, Luis Fayad, Chi Young Ok, Rashmi Kanagal-Shamanna, Holly A Hill, Yixin Yao, Fredrick B Hagemeister, Jason R Westin, Nathan Fowler, Felipe Samaniego, Raphael Steiner, Ranjit Nair, Swaminathan P Iyer, Lucy Navsaria, Maria Badillo, Mantle Cell Research Group, Lei Feng, Huang Xuelin, Graciela M Nogueras Gonzalez, Guofan Xu, Nicolaus Wagner-Bartak, Selvi Thirumurthi, David Santos, Guilin Tang, Pei Lin, Sa A Wang, Jeff Jorgensen, C Cameron Yin, Shaoying Li, Keyur P Patel, Francisco Vega, L Jeffery Medeiros, Christopher R Flowers, Linghua Wang

    Resumen Resumen Esquema Esquema   
• • ·Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

    Página :416-427

    Paul G Richardson, Aurore Perrot, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Jeffrey Shang-Yi Huang, Jiri Minarik, Michele Cavo, H Miles Prince, Laure Malinge, Franck Dubin, Helgi van de Velde, Kenneth C Anderson

    Resumen Resumen Esquema Esquema   
• • ·Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study

    Página :428-438

    Alistair D R Grey, Rebecca Scott, Bina Shah, Peter Acher, Sidath Liyanage, Menelaos Pavlou, Rumana Omar, Frank Chinegwundoh, Prasad Patki, Taimur T Shah, Sami Hamid, Maneesh Ghei, Kayleigh Gilbert, Diane Campbell, Chris Brew-Graves, Nimalan Arumainayagam, Alex Chapman, Laura McLeavy, Angeliki Karatziou, Zayneb Alsaadi, Tom Collins, Alex Freeman, David Eldred-Evans, Mariana Bertoncelli-Tanaka, Henry Tam, Navin Ramachandran, Sanjeev Madaan, Mathias Winkler, Manit Arya, Mark Emberton, Hashim U Ahmed

    Resumen Resumen Esquema Esquema   
• • ·Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

    Página :e105

    Xiaofei Zhu, Yangsen Cao, Wenyu Liu, Xiaoping Ju, Xianzhi Zhao, Lingong Jiang, Yusheng Ye, Gang Jin, Huojun Zhang

    Resumen Resumen Esquema Esquema   
• • ·A comprehensive framework for early-onset colorectal cancer research

    Página :e116

    Cathy Eng, Alexandre A Jácome, Rajiv Agarwal, Muhammad Hashim Hayat, Mariana X Byndloss, Andreana N Holowatyj, Christina Bailey, Christopher H Lieu

    Resumen Resumen Esquema Esquema  
• • ·Toxicity and efficacy of chronomodulated chemotherapy: a systematic review

    Página :e129

    Markella I Printezi, Aoife B Kilgallen, Marinde J G Bond, Urška Štibler, Marrit Putker, Arco J Teske, Maarten J Cramer, Cornelis J A Punt, Joost P G Sluijter, Alwin D R Huitema, Anne M May, Linda W van Laake

    Resumen Resumen Esquema Esquema   
• • ·Essential medicines list in national cancer control plans: a secondary analysis from a global study

    Página :e144-154

    Evangelia Razis, Marie Kassapian, Charitini Andriakopoulou, Yehoda M Martei, Shalini Jayasekar Zurn, Nazik Hammad, Yannick Romero, Urania Dafni, André M Ilbawi, Dario Trapani

    Resumen Resumen Esquema Esquema   
• • ·Granulocyte colony-stimulating factor-associated aortitis

    Página :e155

    Toshiaki Takahashi, Kazumasa Yamamoto, Takeshi Yamaguchi, Yuji Miura, Rika Kizawa